RenalytixAI to Collaborate with AstraZeneca
("RenalytixAI", the "Company")
RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes
for Patients with Chronic Disease
Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease
An estimated 700 million patients worldwide have CKD,1 which is also associated with an increased risk of metabolic and hematologic complications, such as hyperkalemia (elevated levels of potassium in the blood) and anemia.2,3
The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimize utilization of therapeutics in CKD under current standard of care protocols. Based on study outcomes, a multi-center, randomized controlled trial will be initiated to evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalemia. The studies will be conducted in coordination with the
"We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease," said
RenalytixAI and AstraZeneca will use KidneyIntelX with the aim to:
· Help improve physician uptake and patient adherence to existing potassium-binding therapeutics and other approved products in CKD through early identification of previously hidden high-risk patient groups
· Accelerate patient identification and recruitment for clinical trials
· Complement commercialization efforts with outcomes from KidneyIntelX results
"This collaborative approach reflects the shared vision of AstraZeneca and RenalytixAI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way," said
Results from the program are anticipated in early 2021.
For further information, please contact:
|
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: 020 7496 3000 |
|
|
|
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Chronic Kidney Disease
CKD is a serious, progressive condition defined by decreased kidney function (shown by reduced eGFR or markers of kidney damage, or both, for at least three months).5 In
The disease often has no symptoms in its early stages and can go undetected until it is very advanced requiring dialysis or a kidney transplant. The
As kidney function declines, patients face an increased risk of developing other associated CKD complications, such as anemia or hyperkalemia.2,3 Anemia is a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin ("Hb"), a protein in red blood cells that carries oxygen to cells throughout the body.3 If left untreated, anemia of CKD can cause increased hospitalization, morbidity and mortality.9 Hyperkalemia can also be a dangerous condition, characterized by elevated potassium levels in the blood.2 If left untreated, it can cause an irregular heartbeat and can be fatal.
About RenalytixAI
We are a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management in chronic kidney disease to help drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and extensive personalized patient data from electronic health record systems to generate a unique patient risk score. KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to RenalytixAI. Mount Sinai and
About the
The
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: our ability to improve outcomes for patients with chronic disease and develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease, as well as the anticipated benefits of the collaboration with AstraZeneca, including optimizing utilization of existing and novel therapeutics, accelerating patient identification and recruitment for clinical trials and complementing commercialization efforts. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have not yet commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
Media Contacts:
RenalytixAI United States:
Zer0 to 5ive for RenalytixAI
(917) 748-4006
Mount Sinai Hospital System
Phone: +1 212-241-9200
Email: NewsMedia@mssm.edu
References:
1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: asystematic analysis for the Global Burden of Disease Study 2017.The
2.
3.
4. Desai NR, Reed P, Alvarez PJ, et al. The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplement 2013; (3):1-150. Accessed
6.
7. A Hidden Epidemic: More than 850 Million Suffer from Kidney Diseases Worldwide, Organizations Report.
8.
9. Thorp M, Johnson S, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. APSN. 2009;14(2):240-246. doi:10.1111/j.1440-1797.2008.01065.x.
This information is provided by RNS, the news service of the